Hoth Therapeutics Says 100% Of Patients Achieved Primary Endpoint In HT-001 Phase 2A Trial
June 24 (Reuters) - Hoth Therapeutics Inc HOTH.O:
HOTH THERAPEUTICS HT-001 INTERIM RESULTS FIRST-IN-CLASS TOPICAL THERAPY PRESERVES CANCER TREATMENT WHILE RESOLVING DERMATOLOGIC SIDE EFFECTS
HOTH THERAPEUTICS INC - 100% OF PATIENTS ACHIEVED PRIMARY ENDPOINT IN PHASE 2A TRIAL
HOTH THERAPEUTICS INC - TOPICAL THERAPY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

POET Technologies Stock Could Still Surge in 2026, but the Bar for a Breakout Is Higher Now

Tradingkey






